Haemonetics (HAE) AI Stock Analysis

• Market Cap: $2.66B
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): 16.8
• Beta (1Y): 0.74
• Revenue Growth: 0.91%
• EPS Growth: 45.81%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.10
• Shares Outstanding: 48,177,258
• 10 Day Avg. Volume: 1,136,566
• 30 Day Avg. Volume: 1,053,736
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.69
• Enterprise Value/Revenue: 3.34
• Enterprise Value/Gross Profit: 5.96
• Enterprise Value/Ebitda: 12.99
• 1Y Price Target: $73.00
• Price Target Upside: 32.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 68 Neutral
• Price Target: $58.00 ▲(5.40% Upside)

Haemonetics' overall stock score is driven by strong financial performance and positive earnings call insights, indicating robust growth in key areas and effective margin management. However, technical analysis reveals bearish trends, and valuation metrics suggest moderate attractiveness. Addressing revenue growth challenges and leveraging strategic initiatives will be crucial for future performance.

Positive Factors

Earnings

Non-GAAP EPS came in at $1.10, exceeding both the internal estimate and the consensus estimate of $1.02.

Financial Performance

Haemonetics generated $321.4 million in revenue, which exceeded both the internal estimate and the consensus estimate.

Plasma Segment Performance

Plasma revenue came in ahead of expectations by $19M, highlighting strong performance in this segment.

Negative Factors

Competitive Pressures

Increased competition for VASCADE has prompted leadership and sales force changes at HAE.

Interventional Technologies Challenges

The interventional technologies business within the hospital unit declined 7.2% on a reported basis and was down 7.5% organically, rattling investors.

Operational Challenges

The company is facing operational challenges with numbers continuing to move lower off of execution.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation (HAE) is a global healthcare company that specializes in blood management solutions. Founded in 1971 and headquartered in Braintree, Massachusetts, Haemonetics operates in various sectors including blood component collection, transfusion medicine, and surgical blood management. Its core products and services include automated blood collection systems, blood processing equipment, and software solutions designed to enhance the efficiency and safety of blood management practices in hospitals and blood centers worldwide.

How the Company Makes Money

Haemonetics generates revenue primarily through the sale of its medical devices and equipment, which includes automated blood collection systems such as the TEG (Thromboelastography) system and blood component separation technologies. The company also earns income from service contracts, maintenance, and software solutions that accompany its devices, ensuring ongoing support and updates for healthcare providers. Key revenue streams include the sale of consumables used in blood collection processes, which are recurring in nature. Strategic partnerships with blood banks, hospitals, and healthcare systems enhance its market presence and contribute to its earnings by providing integrated solutions that improve patient care and operational efficiency.

Haemonetics Financial Statement Overview

Summary

Haemonetics exhibits strong financial performance with consistent revenue and profit growth, improved capital structure, and effective cash generation. The income statement shows a notable increase in revenue and profit margins, while the balance sheet reflects a stronger equity position with reduced debt. Cash flow is healthy, indicating efficient cash management.

Income Statement

Haemonetics has demonstrated consistent revenue growth with a notable increase from $993 million in 2022 to $1.36 billion in 2025, reflecting a strong upward trend. The gross profit margin has improved to 55.04%, indicating efficient cost management. The net profit margin has also strengthened to 12.32%, showcasing enhanced profitability. Additionally, the EBIT and EBITDA margins have shown positive growth, contributing to overall financial health.

Balance Sheet

The company's debt-to-equity ratio has improved significantly with a reduction in total debt from $808 million in 2024 to $304 million in 2025, reflecting a stronger equity position. The equity ratio of 33.48% implies a stable financial structure, while the return on equity of 20.42% indicates effective utilization of equity capital. Overall, the balance sheet shows a solid financial position, though there remains room for improving the equity ratio further.

Cash Flow

Haemonetics has experienced positive free cash flow growth with an increase from $115 million in 2024 to $142 million in 2025. The operating cash flow to net income ratio stands at 1.08, indicating effective cash generation relative to profit. The free cash flow to net income ratio of 0.85 supports the company's ability to generate cash after capital expenditures. Overall, the cash flow statement reflects a healthy cash position and efficient cash management practices.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.35B	1.36B	1.31B	1.17B	993.20M	870.46M
Gross Profit	754.50M	748.96M	691.55M	615.10M	505.50M	397.84M
EBITDA	346.51M	337.40M	265.58M	249.34M	178.50M	142.25M
Net Income	163.34M	167.68M	117.56M	115.40M	43.38M	79.47M
Balance Sheet
Total Assets	2.46B	2.45B	2.20B	1.93B	1.86B	1.82B
Cash, Cash Equivalents and Short-Term Investments	292.90M	306.76M	178.80M	284.47M	259.50M	192.31M
Total Debt	1.22B	1.22B	807.79M	765.89M	773.59M	707.61M
Total Liabilities	1.58B	1.63B	1.24B	1.12B	1.11B	1.09B
Stockholders Equity	882.30M	820.84M	959.96M	818.00M	749.42M	731.67M
Cash Flow
Free Cash Flow	189.16M	142.45M	115.45M	162.87M	75.75M	71.77M
Operating Cash Flow	226.54M	181.72M	181.75M	273.06M	172.26M	108.81M
Investing Cash Flow	-55.70M	-161.90M	-322.39M	-143.79M	-86.34M	-425.44M
Financing Cash Flow	-227.32M	108.82M	38.16M	-100.36M	-15.75M	367.45M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 55.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Negative. The current price of 55.03 is below the 20-day moving average (MA) of 58.46, below the 50-day MA of 68.15, and below the 200-day MA of 70.14, indicating a bearish trend. The MACD of -4.27 indicates Negative momentum. The RSI at 32.27 is Neutral, neither overbought nor oversold. The STOCH value of 58.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BDX	75 Outperform	$55.63B	35.00	6.26%	2.13%	7.86%	14.24%
HOLX	75 Outperform	$14.82B	27.69	11.38%	―	1.28%	-17.73%
TFX	73 Outperform	$5.62B	29.95	4.36%	1.08%	1.11%	-23.73%
ATR	71 Outperform	$9.20B	24.10	15.36%	1.29%	1.51%	21.70%
HAE	68 Neutral	$2.66B	16.80	18.27%	―	0.91%	45.81%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%
ICUI	49 Neutral	$3.11B	―	-1.78%	―	2.95%	47.92%

Haemonetics Corporate Events

Haemonetics Holds Successful Annual Shareholders Meeting

On July 24, 2025, Haemonetics Corporation held its Annual Meeting of Shareholders, achieving a quorum with 94.95% of shares represented. During the meeting, shareholders elected nine directors for one-year terms, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending March 28, 2026.